Ledipasvir/sofosbuvir
لدیپاسویر/سوفوسبوویر
🦠 Antiinfectives For Systemic UseHCV direct-acting antiviral
Market / country: 🇺🇸 USA
Harvoni (US)
🧮 Dose calculator
Chronic hepatitis C · Regimen source: FDA Harvoni · 2.3FDA Harvoni · 2.4, Table 2
- • Duration per Table 1 (8–24 weeks; with or without ribavirin). Children 17–<35 kg: 45/200 mg; <17 kg: 33.75/150 mg pellets. No renal adjustment. FDA Harvoni · 2.2FDA Harvoni · 2.4, Table 2FDA Harvoni · 2.6
Enter age and weight.
🛡️ Safety & information
Contraindications
- ⛔ When given with ribavirin, ribavirin contraindications also apply. FDA Harvoni · 4
Warnings
- • Boxed warning: HBV reactivation in HCV/HBV co-infection (sometimes fulminant hepatitis and death) — test HBsAg and anti-HBc first. FDA Harvoni · Boxed Warning
- • Serious symptomatic bradycardia with amiodarone (not recommended together); reduced effect with P-gp inducers (rifampin, St John’s wort). FDA Harvoni · 5
Formulations
- 90 mg ledipasvir / 400 mg sofosbuvir tablet — tablet 🇺🇸 USA FDA Harvoni · 3
- 45 mg / 200 mg tablet — tablet 🇺🇸 USA FDA Harvoni · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label: no adequate human data; no adverse developmental outcomes in animals. With ribavirin the combination is contraindicated in pregnancy. FDA Harvoni · 8.1
“No adequate human data are available to establish whether or not HARVONI poses a risk to pregnancy outcomes. In animal reproduction studies, no evidence of adverse developmental outcomes was observed with the components of HARVONI.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Harvoni · 8.2
“When administered to lactating rats, ledipasvir was detected in the plasma of nursing pups likely due to the presence of ledipasvir in milk, without clear effects on nursing pups [see Data ].”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Harvoni · 8.4
“The safety, pharmacokinetics, and efficacy of HARVONI for treatment of HCV genotype 1 and 4 infection in treatment-naïve and treatment-experienced pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis have been established in an open-label, multicenter clinical trial (Study 1116, …”
- 👴 Older adultsNo specific problem stated
Label: no specific difference or dose adjustment stated for older adults. FDA Harvoni · 8.5
“No dosage adjustment of HARVONI is warranted in geriatric patients [see Clinical Pharmacology (12.3) ] .”
- ⚥ Females & males of reproductive potentialUse with caution
Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Harvoni · 8.3
“If HARVONI is administered with ribavirin, the information for ribavirin with regard to pregnancy testing, contraception, and infertility also applies to this combination regimen.”
🔗 Reference links
- FDA (approval record)NDA205834
- DailyMed (FDA label)FDA Harvoni
- MedlinePlus (NIH)❌ None
- WHO ATC/DDDJ05AP51
- Darooyab (Iran)❌ None
🇮🇷 Not found in Iran list Darooyab · search
Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Harvoni · 3FDA Harvoni · 2.3FDA Harvoni · 2.4, Table 2FDA Harvoni · 2.2FDA Harvoni · 2.6FDA Harvoni · 4FDA Harvoni · Boxed WarningFDA Harvoni · 5FDA Harvoni · SPL approval / marketing categoryFDA Harvoni · 8.1FDA Harvoni · 8.2FDA Harvoni · 8.4FDA Harvoni · 8.5FDA Harvoni · 8.3
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · search
- Clinical review⚠ Unverified